Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in Metastatic Urothelial Carcinoma and Other Solid Tumors
NCT06630416Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Nov 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in urothelial carcinoma (UC) and solid tumor, sponsored by Northwestern University. Primary endpoint: Overall Response Rate up to 12 months. Started Nov 2024; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT06630416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630416.